Novo Nordisk A/S
(NYSE : NVO)

( )
NVO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.86%52.990.9%$1958.03m
JNJJohnson & Johnson 0.42%168.340.7%$1218.17m
ABBVAbbVie, Inc. 0.84%134.211.9%$1007.72m
MRKMerck & Co., Inc. -0.40%79.140.7%$922.99m
BMYBristol-Myers Squibb Co. -0.38%62.221.0%$707.05m
LLYEli Lilly & Co. -0.81%237.511.1%$629.80m
AZNAstraZeneca Plc -1.26%57.121.0%$260.90m
NVSNovartis AG -0.36%84.240.2%$193.64m
GSKGlaxoSmithKline Plc -0.50%44.150.2%$185.72m
NVONovo Nordisk A/S -2.14%93.120.1%$158.88m
VTRSViatris, Inc. -0.41%14.620.0%$135.93m
RGENRepligen Corp. -2.07%181.566.7%$101.32m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 8.52%126.250.0%$96.48m
SNYSanofi -0.16%51.320.2%$69.31m
RPRXRoyalty Pharma Plc -0.51%38.930.1%$63.78m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.